Navigation Links
Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
Date:9/18/2009

. These forward-looking statements include, among other things, statements regarding clinical trials, regulatory approvals, competitive offerings, product performance and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looki
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Boston Scientifics Urology/Gynecology Business Forms Marketing Alliance with Bladder Health Network
2. Boston Scientific Statement on the Passing of Senator Edward Kennedy
3. Boston Scientific to Webcast Conference Call Discussing Results of Landmark MADIT-CRT Trial
4. Boston University Periodontal Study on Imagenetix Compound Published in The Journal of Periodontology
5. Boston Scientific Announces European Approval for Its LATITUDE(R) Patient Management System
6. Boston Scientific to Participate in Wachovia Conference
7. Boston Scientifics SpyGlass(R) Direct Visualization System Featured in Broad Range of Clinical Studies at Upcoming Digestive Disease Week(R)
8. FDA Clears Boston Scientifics SpyScope(R) Access and Delivery Catheter for Use in Endoscopic Procedures Throughout Pancreatico-Biliary System
9. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
10. Angiotechs corporate partner, Boston Scientific, announces launch of third-generation TAXUS(R) Element(TM) Stent
11. Boston Scientific Welcomes Launch of Syntax Score Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... (PRWEB) October 29, 2014 Global polyvinyl ... the world economic crisis during 2008-2009, especially in North ... recovered and currently is keeping to a growing trend. ... volume is utilized in the construction segment. In 2013, ... pipes, profiles, tubing, sheets and rigid film. Moreover, the ...
(Date:10/30/2014)... James Sherley says he has been working towards ASCTC ... his days as a principal investigator at the Fox Chase ... Sherley founded the ASCTC as a new Boston biotech start-up ... developed in Sherley’s research over the years since FCCC, first ... and more recently as a senior scientist at the now ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014 Isis Pharmaceuticals, ... therapeutics, today announced that management will present a company overview ... at 8:30 a.m. ET in Boston, MA. ... be available on the "Investors & Media" section of the ... on the Isis website within 48 hours and will be ...
(Date:10/27/2014)... North Carolina (PRWEB) October 27, 2014 ... invited earlier this month to sit down with Bryan Hamilton, ... from RPG Solutions to discuss talent in the Research Triangle ... topics that were highlighted at the roundtable include ... the Triangle, the significance of work/life balance and the unique ...
Breaking Biology Technology:Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 2Global Polyvinyl Chloride Demand Is on Upward Trend Now, Says Merchant Research & Consulting in Its Topical Study 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4Isis Pharmaceuticals to Present at the Nomura Biotechnology Conference 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 2Personify's Ryan Carfley Talks Recruiting with Triangle Business Journal, RPG Solutions 3
... Aug. 1 Medivation, Inc.,(Nasdaq: MDVN ) today ... will present at the BMO Capital Markets 2008 Focus ... Eastern Time at,the Millennium Broadway Hotel in New York., ... and its clinical,development programs for Dimebon for Alzheimer,s and ...
... LITTLE FALLS, N.J., Aug. 1 CANTEL MEDICAL,CORP. ... its Crosstex,International, Inc. subsidiary, effective today. As planned, ... Crosstex, retired effective today,after over 50 years with ... company. Gary Steinberg and Mitchell Steinberg, also,former owners ...
... ROCKVILLE, Md., Aug. 1 Novavax, Inc. (Nasdaq:,NVAX) ... announced,registered direct equity financing of $18 million by ... existing shelf registration statement.,The Company sold 6,686,650 units ... affiliates of the Company. Each unit was comprised,of ...
Cached Biology Technology:Medivation Announces Presentation at the BMO Capital Markets 2008 Focus on Healthcare Conference on August 5 2Cantel Medical Announces Management Succession at Crosstex Healthcare Disposables Subsidiary 2Novavax Announces Closing of $18 Million Registered Direct Offering 2Novavax Announces Closing of $18 Million Registered Direct Offering 3
(Date:10/30/2014)... 2014 Biological membranes are mainly composed of lipid ... solution ions onto lipid membranes helps clarify functional ... provides a quantitative description of the equilibria between ... and Zbigniew Figaszewski from the University of Bialystok, ... these findings, just published in EPJ E ...
(Date:10/29/2014)... to date, researchers have used DNA sequencing to uncover ... Joseph Buxbaum, Ph.D., Icahn School of Medicine at Mount ... of Harvard and MIT, and their colleagues examined more ... unrelated people. They identified changes in 107 genes that ... spectrum disorder (ASD) – a jump from the nine ...
(Date:10/29/2014)... to make their food, but they also need protection from ... a group of molecules in plants that shields them from ... of the American Chemical Society , one team reports on ... Timothy Zwier and colleagues at Purdue University note that the ... serious damage to plant DNA and, as a result, hinder ...
Breaking Biology News(10 mins):Ion adsorption matter in biology 2
... model suggests that inhospitable hydrodgen-sulphide rich waters could have ... oceans. The research, published online this week in the ... the oceans 550-700 million years ago and shows that ... of complex life, were controlled by the biological availability ...
... hybrid nanomaterials, i.e. combinations of synthetic polymers and inorganic (gold, ... at the University of Helsinki in April. Part of ... a billionth of a metre, matter and materials behave in ... known what types of effects the nano version of the ...
... 200-plus research universities that make up ScienceWorksForU.S. today again ... across-the-board cuts to discretionary spending that will result in ... The consequences to the U.S. economy of reduced R&D ... reduction in U.S. GDP over the next nine years ...
Cached Biology News:Toxic oceans may have delayed spread of complex life 2Is nanosilver toxic? 2Is nanosilver toxic? 3Sequester will have a devastating impact on america's research enterprise 2Sequester will have a devastating impact on america's research enterprise 3
Polyclonal Antibody to Coronin / CORO1C This antibody was developed against synthetic peptides corresponding to amino acids 407-420 of human CORO1C....
... Tyrosine Hydroxylase (Ser40) Polyclonal Antibody ... against synthetic phosphopeptide corresponding to ... phospho-Ser40 of rat Tyrosine Hydroxylase ... by sequential chromatography on phospho- ...
Monoclonal Antibody to GLP Immunogen: Ni-NTA purified truncated recombinant GLP expressed in E. Coli strain BL21 (DE3)...
Biotin anti-human CD164...
Biology Products: